Yujiro S. Hata - 19 Aug 2021 Form 4 Insider Report for ENANTA PHARMACEUTICALS INC (ENTA)

Role
Director
Signature
/s/ Nathaniel S. Gardiner as attorney-in-fact
Issuer symbol
ENTA
Transactions as of
19 Aug 2021
Net transactions value
$0
Form type
4
Filing time
23 Aug 2021, 16:44:20 UTC
Previous filing
25 Jun 2021
Next filing
02 Mar 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ENTA Stock Option (right to buy) Award $0 +13,144 $0.000000 13,144 19 Aug 2021 Common Stock 13,144 $48.58 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Such option will become exercisable monthly in substantially equal installments over three years, beginning from the date of grant (August 19, 2021).